Gene · 2012
NIH grants841
NIH grants whose papers are about the gene, through NIH's grant-paper links.
321 to 340 of 841
Download this page as JSON| Grant | Title | EMP1 papers | Newest fiscal year |
|---|---|---|---|
| R25GM095459 | Enabling Access to Cutting-Edge Biomedical and Behavioral Science | 1 | 2021 |
| R33CA225498 | Rapidly scalable platforms for direct in vivo screening of functional drivers in lethal cancers | 1 | 2021 |
| R35CA197734 | Targeted Therapy for Leukemia | 1 | 2021 |
| R35CA210065 | Molecular pathways and targeted therapies in human leukemia | 1 | 2021 |
| U01AA013521 | Neuroimaging of Alcohol-Induced Neuroadaptation: Translation From Animals to Humans | 1 | 2021 |
| U01CA176058 | The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center | 1 | 2021 |
| U01CA217864 | Integrating targeted and immunotherapy to treat genetically heterogeneous cancers | 1 | 2021 |
| U01HG009391 | Connecting transposable elements and regulatory innovation using ENCODE data | 1 | 2021 |
| U24ES026699 | The WashU TaRGET Environmental Epigenomics Data Coordination Center | 1 | 2021 |
| U54CA209992 | Analysis of the regulatory networks regulating district stem cell-like states in aggressive cancers | 1 | 2021 |
| U54CA209997 | Structural and Functional Biology-based analysis of non-oncogene cancer dependencies | 1 | 2021 |
| R15GM116032 | Medicinal Chemistry and Biomedical Studies of Open-Chain Mimics of Ipomoeassin Natural Glycoresins | 3 | 2020 |
| DP5OD023072 | An aminoacyl tRNA synthetase is a nitrogen sensor that activates TOR in plants | 1 | 2020 |
| DP5OD023098 | Development, characterization and application of CRISPR/Cas9 gene drive technologies and related active genetic elements to benefit research and society at large | 1 | 2020 |
| F31AA028180 | Network based approach to identify alcohol dependences associated hub genes for targeted methylation analysis | 1 | 2020 |
| F31DE028480 | Molecular analysis of the oncogenic role of p63 in the development and progression of oral squamous cell carcinomas | 1 | 2020 |
| K24HL107643 | Mentored Patient Oriented Research in Cardiometabolic Disease | 1 | 2020 |
| P20CA233255 | Precision Interception of Aggressive Prostate Cancer in African American Men | 1 | 2020 |
| P30AG019610 | Arizona Alzheimer's Disease Core Center | 1 | 2020 |
| P30ES000260 | Research in Environmental Health Sciences | 1 | 2020 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2012/grants?page=17